Grace Adaji

Ms. Grace Adaji

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2026 in Discover Chemistry
Verified
Journal Article
Open access
PDF file
EOEnayi Onaji
Enayi Onaji
GAGrace Adaji
Grace Adaji
CAChukwunenye Christopher Azubuike
Chukwunenye Christopher Azubuike
MAMukhtar Sani Adam
Mukhtar Sani Adam
LALucky Apeh
Lucky Apeh
EOEdwin Ameh Ojila
Edwin Ameh Ojila
Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by the absence of conventional hormonal receptors, leading to intrinsic resistance to standard therapies and poor clinical outcomes. Topoisomerase I (TOP1) and Topoisomerase II alpha (TOP2A), essential enzymes for DNA replication and transcription, have emerged as promising co-targets to overcome this therapeutic resistance. This study employed an integrated in-silico pipeline to discover novel dual-targeting inhibitors against both TOP1 and TOP2A. A structure-based pharmacophore model (AAHRR_7) was developed and rigorously validated, demonstrating high predictive power. Subsequent virtual screening of a ZINC in-trial compound library identified 475 hits, which were advanced to molecular docking against the crystal structures of TOP1 (PDB: 1T8I) and TOP2A (PDB: 4FM9). This process yielded 15 top-ranked compounds with significantly superior predicted binding affinities compared to reference inhibitors. MM/GBSA refinement and systematic ADMET profiling further prioritized two in-silico candidate molecules ZINC13740825 and ZINC00586527 which exhibited robust binding free energies and favorable drug-like properties with low predicted toxicity. Quantitative structure-activity relationship (QSAR) models and Molecular Dynamics Simulation studies confirmed their potent predicted inhibitory activity and complex stability against both targets. These findings highlight the potential of these identified compounds as promising dual TOP1/TOP2A inhibitors for TNBC therapy, offering a strategic avenue to combat resistance mechanisms. Further experimental validation is warranted to translate these computational insights into therapeutic candidates.

11 November 2025 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
GAGrace Adaji
Grace Adaji
AHAsmau Nasir Hamza
Asmau Nasir Hamza
Endometrial cancer is one of the most common gynecological cancers, with new global cases of approximately 420,000 new cases and 98,000 global deaths annually. Emerging evidence suggests that the EP2 receptor plays a critical role in tumor progression, angiogenesis, and immune evasion. Withanolides, a class of naturally occurring compounds, possess anticancer activity; however, the effect of the EP2 receptor in endometrial cancer remains largely unexplored. This study aims to explore the interaction between withanolides and the EP2 receptor using molecular docking techniques, with PF-04418948 as the reference antagonist. A select number of these ligands, with anticancer activity, were evaluated for their absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, and those with favorable drug-like properties, low toxicity profile, and no more than one Lipinski’s rule violation were docked to EP2 (PDB ID: 7CX2). Molecular docking studies revealed three ligands, (Pubchem 161671, 265237, and 21679027) with significantly higher binding affinity scores compared to that of the reference compound. Pubchem 161671 showed the highest binding affinity at −12.6 kcal/mol. Post-dock analysis revealed interactions with key amino acids, VAL89, LEU298, SER305, and MET31, which are essential for the antagonist activity of the EP2 receptor enzyme. Significant interaction with critical amino acid residues suggested potential inhibition of EP2 receptor activity, offering a potential therapeutic approach for treating endometrial cancer. Overall, this study proffers a deeper understanding of the potential of withanolides as leads for EP2 targeted therapy in endometrial cancer.